{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:06:12Z","timestamp":1793981172468,"version":"4.8.0"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:sec id=\"ab-jrv230014-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Each year in the US, approximately 100\u202f000 people are treated for cervical precancer, 14\u202f000 people are diagnosed with cervical cancer, and 4000 die of cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230014-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Essentially all cervical cancers worldwide are caused by persistent infections with one of 13 carcinogenic human papillomavirus (HPV) genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV vaccination at ages 9 through 12 years will likely prevent more than 90% of cervical precancers and cancers. In people with a cervix aged 21 through 65 years, cervical cancer is prevented by screening for and treating cervical precancer, defined as high-grade squamous intraepithelial lesions of the cervix. High-grade lesions can progress to cervical cancer if not treated. Cervicovaginal HPV testing is 90% sensitive for detecting precancer. In the general population, the risk of precancer is less than 0.15% over 5 years following a negative HPV test result. Among people with a positive HPV test result, a combination of HPV genotyping and cervical cytology (Papanicolaou testing) can identify the risk of precancer. For people with current precancer risks of less than 4%, repeat HPV testing is recommended in 1, 3, or 5 years depending on 5-year precancer risk. For people with current precancer risks of 4% through 24%, such as those with low-grade cytology test results (atypical squamous cells of undetermined significance [ASC-US] or low-grade squamous intraepithelial lesion [LSIL]) and a positive HPV test of unknown duration, colposcopy is recommended. For patients with precancer risks of less than 25% (eg, cervical intraepithelial neoplasia grade 1 [CIN1] or histologic LSIL), treatment-related adverse effects, including possible association with preterm labor, can be reduced by repeating colposcopy to monitor for precancer and avoiding excisional treatment. For patients with current precancer risks of 25% through 59% (eg, high-grade cytology results of ASC cannot exclude high-grade lesion [ASC-H] or high-grade squamous intraepithelial lesion [HSIL] with positive HPV test results), management consists of colposcopy with biopsy or excisional treatment. For those with current precancer risks of 60% or more, such as patients with HPV-16\u2013positive HSIL, proceeding directly to excisional treatment is preferred, but performing a colposcopy first to confirm the need for excisional treatment is acceptable. Clinical decision support tools can facilitate correct management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230014-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Approximately 100\u202f000 people are treated for cervical precancer each year in the US to prevent cervical cancer. People with a cervix should be screened with HPV testing, and if HPV-positive, genotyping and cytology testing should be performed to assess the risk of cervical precancer and determine the need for colposcopy or treatment. HPV vaccination in adolescence will likely prevent more than 90% of cervical precancers and cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.13174","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:21:11Z","timestamp":1691493671000},"page":"547","source":"Crossref","is-referenced-by-count":506,"title":["Cervical Cancer Screening"],"prefix":"10.1001","volume":"330","author":[{"given":"Rebecca B.","family":"Perkins","sequence":"first","affiliation":[{"name":"Boston University School of Medicine, Chobanian & Avedisian School of Medicine, Boston Medical Center, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Wentzensen","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Guido","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"UPMC Magee-Women\u2019s Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schiffman","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jrv230014r2","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ijc.v131.10","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv230014r3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1055-9965.EPI-20-0846","article-title":"Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study.","volume":"30","author":"Mix","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"jrv230014r4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer.","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv230014r5","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1002\/cam4.v10.12","article-title":"A population study of screening history and diagnostic outcomes of women with invasive cervical cancer.","volume":"10","author":"Benard","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"jrv230014r6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2010.09.021","article-title":"Screening history in women with cervical cancer in a Danish population-based screening program.","volume":"120","author":"Kirschner","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv230014r7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2022.09.012","article-title":"Underscreening, overscreening, and guideline-adherent cervical cancer screening in a national cohort.","volume":"162","author":"Lee","year":"2022","journal-title":"Gynecol Oncol"},{"key":"jrv230014r8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2046-4053-2-35","article-title":"Screening for cervical cancer: a systematic review and meta-analysis.","volume":"2","author":"Peirson","year":"2013","journal-title":"Syst Rev"},{"key":"jrv230014r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs.","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"2","key":"jrv230014r10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"20","key":"jrv230014r12","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMsr2030640","article-title":"The IARC perspective on cervical cancer screening.","volume":"385","author":"Bouvard","year":"2021","journal-title":"N Engl J Med"},{"key":"jrv230014r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2023.199068","article-title":"Elimination of reserve cells for prevention of HPV-associated cervical cancer.","volume":"329","author":"Reich","year":"2023","journal-title":"Virus Res"},{"issue":"9590","key":"jrv230014r14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer.","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"jrv230014r15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.v141.4","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type.","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv230014r16","doi-asserted-by":"publisher","first-page":"14064","DOI":"10.1038\/s41598-021-93485-1","article-title":"Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.","volume":"11","author":"Mendoza","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"jrv230014r17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.","volume":"21","author":"Porras","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"jrv230014r18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-Year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries.","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jrv230014r19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/ijc.v147.6","article-title":"A study of the risks of CIN3+ detection after multiple rounds of HPV testing: results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.","volume":"147","author":"Hammer","year":"2020","journal-title":"Int J Cancer"},{"key":"jrv230014r20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad043","article-title":"Human papillomavirus intermittence and risk factors associated with first detections and redetections in the Ludwig-McGill cohort study of adult women.","author":"Malag\u00f3n","year":"2023","journal-title":"J Infect Dis"},{"issue":"9","key":"jrv230014r21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/fmb.11.87","article-title":"Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.","volume":"6","author":"Sahasrabuddhe","year":"2011","journal-title":"Future Microbiol"},{"issue":"9","key":"jrv230014r22","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women.","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"jrv230014r23","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/1055-9965.EPI-12-0905","article-title":"Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.","volume":"21","author":"Clarke","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"jrv230014r24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/jamaoncol.2018.4270","article-title":"Five-year risk of cervical precancer following p16\/Ki-67 dual-stain triage of HPV-positive women.","volume":"5","author":"Clarke","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"jrv230014r25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program.","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"jrv230014r26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/ijc.v150.3","article-title":"Clinical validation of p16\/Ki-67 dual-stained cytology triage of HPV-positive women: results from the IMPACT trial.","volume":"150","author":"Wright","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv230014r27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/jnci\/djaa066","article-title":"Accuracy and efficiency of deep-learning-based automation of dual stain cytology in cervical cancer screening.","volume":"113","author":"Wentzensen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"jrv230014r28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ygyno.2014.08.014","article-title":"Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: a population-based epidemiologic study of 51,842 women in Brazil.","volume":"135","author":"Nogueira-Rodrigues","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"jrv230014r29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ygyno.2017.06.003","article-title":"Why does cervical cancer occur in a state-of-the-art screening program?","volume":"146","author":"Castle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv230014r30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/LGT.0000000000000667","article-title":"Contribution of etiologic cofactors to CIN3+ risk among women with human papillomavirus-positive screening test results.","volume":"26","author":"Demarco","year":"2022","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"jrv230014r31","doi-asserted-by":"publisher","first-page":"366.e1","DOI":"10.1016\/j.ajog.2020.10.001","article-title":"Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017.","volume":"224","author":"Saraiya","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"jrv230014r32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.22.01424","article-title":"Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype.","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"jrv230014r34","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1200\/JCO.2017.75.3442","article-title":"Epidemiologic evidence that excess body weight increases risk of cervical cancer by decreased detection of precancer.","volume":"36","author":"Clarke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv230014r35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-132-9-200005020-00003","article-title":"Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care?","volume":"132","author":"Wee","year":"2000","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv230014r36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/infdis\/jix244","article-title":"Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003-2014.","volume":"216","author":"Oliver","year":"2017","journal-title":"J Infect Dis"},{"issue":"15","key":"jrv230014r37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.15585\/mmwr.mm6815a1","article-title":"Estimated number of cases of high-grade cervical lesions diagnosed among women\u2014United States, 2008 and 2016.","volume":"68","author":"McClung","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"jrv230014r38","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee On Immunization Practices.","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-05","key":"jrv230014r39","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"jrv230014r40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jrv230014r41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States.","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann Intern Med"},{"issue":"12","key":"jrv230014r42","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/ijc.v138.12","article-title":"Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study.","volume":"138","author":"Herweijer","year":"2016","journal-title":"Int J Cancer"},{"issue":"35","key":"jrv230014r43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.15585\/mmwr.mm7135a1","article-title":"National vaccination coverage among adolescents aged 13-17 years\u2014National Immunization Survey-Teen, United States, 2021.","volume":"71","author":"Pingali","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jrv230014r44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","article-title":"ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women.","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"7","key":"jrv230014r46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement.","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"jrv230014r47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening.","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jrv230014r48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M17-1609","article-title":"Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study.","volume":"168","author":"Castle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"jrv230014r49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines.","volume":"24","author":"Egemen","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"jrv230014r50","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ypmed.2019.04.010","article-title":"Trends in cervical cancer incidence rates by age, race\/ethnicity, histological subtype, and stage at diagnosis in the United States.","volume":"123","author":"Islami","year":"2019","journal-title":"Prev Med"},{"issue":"5","key":"jrv230014r51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3322\/caac.v70.5","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"jrv230014r52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ygyno.2021.05.035","article-title":"Eligibility for cervical cancer screening exit: comparison of a national and safety net cohort.","volume":"162","author":"Mills","year":"2021","journal-title":"Gynecol Oncol"},{"key":"jrv230014r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.105880","article-title":"Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45-65 years of age in the United States.","volume":"130","author":"Harper","year":"2020","journal-title":"Prev Med"},{"issue":"4","key":"jrv230014r54","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/LGT.0000000000000435","article-title":"Cervical cancer incidence among elderly women in Massachusetts compared with younger women.","volume":"22","author":"Feldman","year":"2018","journal-title":"J Low Genit Tract Dis"},{"key":"jrv230014r55","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ypmed.2018.07.005","article-title":"How confident can we be in the current guidelines for exiting cervical screening?","volume":"114","author":"Gravitt","year":"2018","journal-title":"Prev Med"},{"key":"jrv230014r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106625","article-title":"Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: a population-based case-control study.","volume":"149","author":"Castanon","year":"2021","journal-title":"Prev Med"},{"issue":"2","key":"jrv230014r57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ygyno.2012.04.037","article-title":"Screening history preceding a diagnosis of cervical cancer in women age 65 and older.","volume":"126","author":"Dinkelspiel","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"jrv230014r58","doi-asserted-by":"publisher","first-page":"228.e1","DOI":"10.1016\/j.ajog.2021.09.012","article-title":"Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.","volume":"226","author":"Munshi","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"jrv230014r59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/LGT.0000000000000685","article-title":"Risk-based cervical consensus guidelines: methods to determine management if less than 5 years of data are available.","volume":"26","author":"Egemen","year":"2022","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"jrv230014r60","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/LGT.0000000000000334","article-title":"ASCCP colposcopy standards: risk-based colposcopy practice.","volume":"21","author":"Wentzensen","year":"2017","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"jrv230014r61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/LGT.0000000000000322","article-title":"Evidence-based consensus recommendations for colposcopy practice for cervical cancer prevention in the United States.","volume":"21","author":"Wentzensen","year":"2017","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"jrv230014r62","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/01.AOG.0000220505.18525.85","article-title":"Number of cervical biopsies and sensitivity of colposcopy.","volume":"108","author":"Gage","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"jrv230014r63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2014.55.9948","article-title":"Multiple biopsies and detection of cervical cancer precursors at colposcopy.","volume":"33","author":"Wentzensen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv230014r64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/LGT.0000000000000710","article-title":"Colposcopy standards: guidelines for endocervical curettage at colposcopy.","volume":"27","author":"Massad","year":"2023","journal-title":"J Low Genit Tract Dis"},{"issue":"11","key":"jrv230014r65","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.5858\/2004-128-1224-BIARRP","article-title":"Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology.","volume":"128","author":"Davey","year":"2004","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"jrv230014r66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/LGT.0b013e31825c31dd","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.","volume":"16","author":"Darragh","year":"2012","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"jrv230014r67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","article-title":"CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples.","volume":"26","author":"Carreon","year":"2007","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"jrv230014r68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/LGT.0000000000000530","article-title":"A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines.","volume":"24","author":"Demarco","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"3","key":"jrv230014r69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/AOG.0b013e3181d068a3","article-title":"Loop electrosurgical excision procedure and risk of preterm birth.","volume":"115","author":"Werner","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"9","key":"jrv230014r70","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bjo.2011.118.issue-9","article-title":"The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis.","volume":"118","author":"Bruinsma","year":"2011","journal-title":"BJOG"},{"issue":"4","key":"jrv230014r71","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/AOG.0000000000000174","article-title":"Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis.","volume":"123","author":"Conner","year":"2014","journal-title":"Obstet Gynecol"},{"key":"jrv230014r72","doi-asserted-by":"publisher","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"jrv230014r73","doi-asserted-by":"publisher","first-page":"742.e1","DOI":"10.1016\/j.ajog.2022.06.051","article-title":"Active expectancy as alternative to treatment for cervical intraepithelial neoplasia grade 2 in women aged 25 to 30 years: ExCIN2-a prospective clinical multicenter cohort study.","volume":"227","author":"Kyleb\u00e4ck","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"jrv230014r74","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/LGT.0000000000000604","article-title":"The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: a systematic review and meta-analysis.","volume":"25","author":"Loopik","year":"2021","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"jrv230014r75","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/00128360-199904000-00005","article-title":"A prospective study of biopsy-confirmed cervical intraepithelial neoplasia grade 1: colposcopic, cytological, and virological risk factors for progression.","volume":"3","author":"Greenberg","year":"1999","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"jrv230014r76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/GMIT.GMIT_56_18","article-title":"Loop electrosurgical excision procedure versus cryotherapy in the treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of randomized controlled trials.","volume":"7","author":"D\u2019Alessandro","year":"2018","journal-title":"Gynecol Minim Invasive Ther"},{"issue":"1","key":"jrv230014r78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12905-020-00901-1","article-title":"Defining the short-term disease recurrence after loop electrosurgical excision procedure (LEEP).","volume":"20","author":"Papalia","year":"2020","journal-title":"BMC Womens Health"},{"issue":"9","key":"jrv230014r79","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/ijc.v142.9","article-title":"Long-term risk of cervical cancer following conization of cervical intraepithelial neoplasia grade 3\u2014a Danish nationwide cohort study.","volume":"142","author":"Sand","year":"2018","journal-title":"Int J Cancer"},{"issue":"7526","key":"jrv230014r80","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.38663.459039.7C","article-title":"Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study.","volume":"331","author":"Kalliala","year":"2005","journal-title":"BMJ"},{"key":"jrv230014r81","doi-asserted-by":"publisher","first-page":"f7361","DOI":"10.1136\/bmj.f7361","article-title":"Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality.","volume":"348","author":"Strander","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"jrv230014r82","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ygyno.2021.08.015","article-title":"Disparities in cervical cancer survival in the United States by race and stage at diagnosis: an analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3).","volume":"163","author":"Matz","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2S","key":"jrv230014r83","first-page":"S19","article-title":"Cervical cancer disparities.","volume":"115","author":"Perkins","year":"2023","journal-title":"J Natl Med Assoc"},{"key":"jrv230014r84","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.pvr.2018.02.003","article-title":"IPVS statement moving towards elimination of cervical cancer as a public health problem.","volume":"5","author":"Garland","year":"2018","journal-title":"Papillomavirus Res"},{"issue":"4","key":"jrv230014r85","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/ijgc-2020-001285","article-title":"World Health Organization call for action to eliminate cervical cancer globally.","volume":"30","author":"Gultekin","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"jrv230014r86","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.acap.2021.05.018","article-title":"Impact of a multilevel quality improvement intervention using national partnerships on human papillomavirus vaccination rates.","volume":"21","author":"Perkins","year":"2021","journal-title":"Acad Pediatr"},{"issue":"2S","key":"jrv230014r87","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.acap.2017.11.001","article-title":"Early outcomes of a multilevel human papillomavirus vaccination pilot intervention in federally qualified health centers.","volume":"18","author":"Fisher-Borne","year":"2018","journal-title":"Acad Pediatr"},{"issue":"1","key":"jrv230014r88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/LGT.0000000000000648","article-title":"Long-term multilevel intervention impact on human papillomavirus vaccination rates spanning the COVID-19 pandemic.","volume":"26","author":"Casey","year":"2022","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"jrv230014r89","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2737","article-title":"Improving HPV vaccination rates: a stepped-wedge randomized trial.","volume":"146","author":"Perkins","year":"2020","journal-title":"Pediatrics"},{"issue":"1","key":"jrv230014r90","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1764","article-title":"Announcements versus conversations to improve HPV vaccination coverage: a randomized trial.","volume":"139","author":"Brewer","year":"2017","journal-title":"Pediatrics"},{"issue":"19","key":"jrv230014r91","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1016\/j.vaccine.2022.03.054","article-title":"Healthcare professional\u2019s promotional strategies in improving human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review.","volume":"40","author":"Efua Sackey","year":"2022","journal-title":"Vaccine"},{"key":"jrv230014r93","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ypmed.2019.05.003","article-title":"Cervical and colorectal cancer screening prevalence before and after Affordable Care Act Medicaid expansion.","volume":"124","author":"Huguet","year":"2019","journal-title":"Prev Med"},{"key":"jrv230014r1","unstructured":"Cervix. Cancer Statistics Center. American Cancer Society. Accessed July 31, 2023. https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.20975355.1746569515.1533055502-552426982.1496697483#!\/cancer-site\/Cervix"},{"key":"jrv230014r11","unstructured":"Cervical Cancer Screening: IARC Handbooks of Cancer Prevention. Vol 18. IARC Publications; 2022. Accessed December 23, 2022. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Handbooks-Of-Cancer-Prevention\/Cervical-Cancer-Screening-2022"},{"key":"jrv230014r33","unstructured":"Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Centers for Disease Control and Prevention. Accessed October 10, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/human-0?view=full"},{"key":"jrv230014r45","unstructured":"ASCCP clinical practice statement: evaluation of the cervix in patients with abnormal vaginal bleeding. Published online February 2017. Accessed July 20, 2023. https:\/\/www.asccp.org\/Assets\/9d92e617-858f-43f3-af62-44adf76cfc67\/636220616039000000\/vaginal-bleeding-statement-final-02-06-17-pdf?"},{"key":"jrv230014r77","unstructured":"WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia; 2011. Accessed December 2, 2019. World Health Organization. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44776\/9789241502856_eng.pdf;jsessionid=4E43B299F3AEAD2DA5FD62809C40F101?sequence=1"},{"key":"jrv230014r92","unstructured":"Closing gaps in cancer screening: connecting people, communities, and systems to improve equity and access. cervical cancer companion brief. Presidents Cancer Panel. February 2022. Accessed April 15, 2022. https:\/\/prescancerpanel.cancer.gov\/report\/cancerscreening\/pdf\/PresCancerPanel_CancerScreening_CB_Cervical_Feb2022.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2807981\/jama_perkins_2023_rv_230014_1691423404.34694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:21:22Z","timestamp":1691493682000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807981"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.13174","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}